<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390594</url>
  </required_header>
  <id_info>
    <org_study_id>2020-002</org_study_id>
    <nct_id>NCT04390594</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal</brief_title>
  <acronym>SEN-CoV-Fadj</acronym>
  <official_title>Multicentre, Open Label, Randomised, Adaptative Clinical Trial of Efficacy and Safety of Treatment Regimens in Adult COVID-19 Patients in Senegal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Pasteur de Dakar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fann Hospital, Senegal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Senegal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diamniadio Children Hospital, Senegal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalal Jamm Hospital, Senegal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Pasteur de Dakar</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID-19 is an emerging pandemic disease affecting most countries including Senegal, caused
      by the new coronavirus (SARS-CoV-2) which was first detected in the city of Wuhan in China in
      December 2019. A rapid spread of the disease has occurred at a global scale, associated with
      a mortality rate of 3.4%. The first case in Africa was declared on February 15, 2020 in Egypt
      and the first case in Senegal was declared on March 2nd, 2020.

      In this context, the SEN-CoV-Fadj clinical trial aims to evaluate efficacy and safety, among
      adults, of different therapeutic regimens considered optimal according to current knowledge,
      as well as available and adapted to Sub-Saharan Africa. This trial is nested into a cohort of
      confirmed cases of COVID-19 in Senegal aiming to understand the main clinical, biological,
      virologic and immunological characteristics of the infection. The protocol of the cohort is
      based and adapted from the International Severe Acute Respiratory and Emerging Infection
      Consortium (ISARIC) / World Health Organization (WHO) Clinical Characterisation Protocol
      (CCP).

      Two therapeutic regimens have been eligible in the short term for SEN-CoV-Fadj:
      Hydroxychloroquine (HCQ) on one hand, and the combination of Hydroxychloroquine and
      Azithromycin (HCQ + AZM) on the other hand.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COVID-19 is an emerging pandemic disease affecting most countries including Senegal, caused
      by the new coronavirus (SARS-CoV-2) which was first detected in the city of Wuhan in China in
      December 2019. A rapid spread of the disease has occurred at a global scale, associated with
      a mortality rate of 3.4%. The first case in Africa was declared on February 15, 2020 in Egypt
      and the first case in Senegal was declared on March 2nd, 2020.

      In this context, the SEN-CoV-Fadj clinical trial aims to evaluate efficacy and tolerance,
      among adults, of different therapeutic options considered optimal according to current
      knowledge, as well as available and adapted to Sub-Saharan Africa. This trial is nested into
      a cohort of confirmed cases of COVID-19 in Senegal aiming to understand the main clinical,
      biological, virologic and immunological characteristics of the infection. The protocol of the
      cohort is based and adapted from the International Severe Acute Respiratory and Emerging
      Infection Consortium (ISARIC) / World Health Organization (WHO) Clinical Characterisation
      Protocol (CCP).

      Two therapeutic regimens have been retained in the short term for SEN-CoV-Fadj:
      Hydroxychloroquine (HCQ) on one hand, and the combination of Hydroxychloroquine and
      Azithromycin (HCQ + AZM) on the other hand.

      The primary objective is to :

      Evaluate and compare viral clearance between the different therapeutic interventions.

      The secondary objectives are to:

        -  Evaluate and compare efficacy of the different therapeutic regimens

        -  Evaluate and compare the tolerance of the different therapeutic regimens

        -  Evaluate and compare the impact of the different therapeutic interventions on the length
           of hospitalization and other clinical measurements
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SARS-CoV-2 viral load level</measure>
    <time_frame>Day 7</time_frame>
    <description>Real time-PCR (RT-PCR) result of the naso- and oro-pharyngeal sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital status</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with serious adverse events reported during the clinical trial.</measure>
    <time_frame>through study completion, an average of 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>through hospitalization, an average of 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization in a resuscitation unit</measure>
    <time_frame>through hospitalization, an average of 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of oxygen therapy</measure>
    <time_frame>through hospitalization, an average of 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum quick SOFA (qSOFA) score during hospitalisation</measure>
    <time_frame>through hospitalization, an average of 2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">258</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine (HCQ)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine + Azithromycin (HCQ + AZM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>800 mg in two doses at Day 1, then 200 mg per os twice a day from Day 2 to Day 10.
If creatinine clearance becomes inferior to 50 mL/min, the posology will be reduced to 200 mg per day.</description>
    <arm_group_label>Hydroxychloroquine (HCQ)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine + Azithromycin</intervention_name>
    <description>Hydroxychloroquine 800 mg in two doses at Day 1, then 200 mg per os twice a day from Day 2 to Day 10, and Azithromycin 500 mg at Day 1, then 250 mg each day from Day 2 to Day 5 included.
If creatinine clearance becomes inferior to 50 mL/min, the Hydroxychloroquine posology will be reduced to 200 mg per day.</description>
    <arm_group_label>Hydroxychloroquine + Azithromycin (HCQ + AZM)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed cases of SARS-CoV-2 infection hospitalized in reference services identified
             by the Ministry of Health and Social Action of Senegal

          -  Adults (≥18 years if not married, ≥15 years if married woman, ≥16 years if married
             man)

          -  Full understanding and consent to participate to the trial

          -  No counter-indications to taking the tested treatments

        Exclusion Criteria:

          -  Pregnant or breastfeeding woman

          -  Corrected QT interval (QTc) &gt;500ms

          -  Heart electrical dysfunction: atrioventricular block Mobitz type II second-degree,
             high-grade or complete without a functioning pacemaker

          -  Uncontrolled and clinically significant heart diseases, such as arrhythmia, angina or
             decompensated congestive heart failure

          -  Kidney failure (Cl &lt; 30 mL/min)

          -  Known allergy to the studied treatment regimen

          -  Other contraindications with the studied treatment regimen

          -  Known drug-drug interaction with a treatment usually taken by the participant
             contraindicating one of the studied treatment regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moussa Seydi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fann Hospital, Senegal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amadou A. Sall, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut Pasteur de Dakar, Senegal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabien Taieb, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Pasteur de Dakar, Senegal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabien Taieb, MD, PhD</last_name>
    <phone>00221770979235</phone>
    <email>Fabien.taieb@pasteur.sn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Moussa Seydi, MD</last_name>
    <phone>002218691881</phone>
    <email>seydim@u.washington.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Infectious and Tropical Diseases Department, Fann Hospital</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
    <contact>
      <last_name>Moussa Seydi, MD</last_name>
      <phone>002218691881</phone>
      <email>seydim@u.washington.edu</email>
    </contact>
    <contact_backup>
      <last_name>Aissatou Lakhe, MD</last_name>
      <phone>00221775417301</phone>
      <email>aissatoulakhe@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Khardiata D. Mbaye, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aissatou Lakhe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pape S. Ba, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louise Fortes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maguette N. Fall, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oumar Kane, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diamniadio Children Hospital</name>
      <address>
        <city>Diamniadio</city>
        <country>Senegal</country>
      </address>
    </facility>
    <contact>
      <last_name>Maguette N. Fall, MD</last_name>
      <phone>00221777098736</phone>
      <email>maguifall4@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Aissatou Lakhe, MD</last_name>
      <phone>00221775417301</phone>
      <email>aissatoulakhe@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Maguette N. Fall, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aissatou Lakhe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pape S. Ba, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dalal Jamm Hospital</name>
      <address>
        <city>Guédiawaye</city>
        <country>Senegal</country>
      </address>
    </facility>
    <contact>
      <last_name>Louise Fortes, MD</last_name>
      <phone>00221775595333</phone>
      <email>louisefortes@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Fatou SD Ndiaye, MD</last_name>
      <email>kinepierre1@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Louise Fortes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fatou SD Ndiaye, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abdoul Kane, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aissatou Lakhe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pape S. Ba, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Senegal</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Senegal</keyword>
  <keyword>Hydroxychloroquine</keyword>
  <keyword>Azithromycin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

